Imad Hanna

发表

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

M. Jamei, X. Chu, K. Hillgren, 2013, Drug Metabolism and Disposition.

Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.

T. Heimbach, Imad Hanna, G. Sunkara, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Yuichi Sugiyama, Hong Shen, Aleksandra Galetin, 2018, Clinical pharmacology and therapeutics.

Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition

Imad Hanna, John Davis, B. Zhu, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.

Imad Hanna, A. Drollmann, E. Greco, 2021, Pulmonary pharmacology & therapeutics.

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Y. Sugiyama, K. Brouwer, X. Chu, 2022, Clinical pharmacology and therapeutics.

Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model.

T. Heimbach, Imad Hanna, Tsu-han Lin, 2017, Journal of pharmaceutical sciences.

Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions

Sophie P. Chung, Shibing Deng, M. Jamei, 2013, Drug Metabolism and Disposition.

DMD050542 1367..1374

Sophie P. Chung, Shibing Deng, M. Jamei, 2013 .

Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.

D. Bednarczyk, Imad Hanna, K. Leung, 2014, Journal of medicinal chemistry.

Intestinal Transporter-Associated Drug Absorption and Toxicity.

Imad Hanna, Yaru Xue, Guoyu Pan, 2019, Advances in experimental medicine and biology.

Management and Mitigation of Human Drug-drug Interaction Risks in the Drug Discovery and Development Phases

Imad Hanna, H. Einolf, 2014 .

Drug Transporters in Drug Interactions and Disposition

Imad Hanna, R. Pelis, 2012 .

Genetic Diversity in Drug Transporters: Impact in African Populations

Imad Hanna, I. Rajman, Laura Knapp, 2020, Clinical and translational science.

Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects

J. Schoepfer, Imad Hanna, F. Hourcade‐Potelleret, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline

Imad Hanna, J. Flarakos, J. Mangold, 2017, Xenobiotica; the fate of foreign compounds in biological systems.

A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters

Imad Hanna, Péter Tátrai, B. Poller, 2019, Drug Metabolism and Disposition.

Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli

Imad Hanna, A. Zaks, M. J. Homann, 2005, Journal of Industrial Microbiology and Biotechnology.

A Plasma Concentration of α-Ketoglutarate Influences the Kinetic Interaction of Ligands with Organic Anion Transporter 1

Imad Hanna, R. Pelis, J. Renfro, 2014, Molecular Pharmacology.

Predicting oral absorption for compounds outside the rule of five property space.

B. Faller, Imad Hanna, B. Poller, 2021, Journal of pharmaceutical sciences.

Assessment of pharmacokinetic drug‐drug interaction between pradigastat and atazanavir or probenecid

Imad Hanna, A. Mendonza, S. Neelakantham, 2016, Journal of clinical pharmacology.

Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects

Imad Hanna, S. Rebello, V. Jarugula, 2012, European Journal of Clinical Pharmacology.

Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.

Imad Hanna, S. Rebello, G. Sunkara, 2015, International journal of clinical pharmacology and therapeutics.

Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches

Imad Hanna, P. Hollenberg, Paul F Hollenberg, 2013, Xenobiotica; the fate of foreign compounds in biological systems.